Skip to content

Clinical Study on the Treatment of Qi and Blood Deficiency Type Geriatric Weakness with Danggui Buxue Tang

Clinical Study on the Treatment of Qi and Blood Deficiency Type Geriatric Weakness with Danggui Buxue Tang

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2026000580
Enrollment
Unknown
Registered
2026-03-18
Start date
2026-01-05
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Geriatric frailty

Interventions

Observation group:Basic intervention plus Huangqi Danggui Oral Liquid

Sponsors

Xi'an City Traditional Chinese Medicine Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Agree to participate in this clinical trial and sign the informed consent form; (2) Meet the Western medical diagnostic criteria for geriatric frailty; (3) Traditional Chinese Medicine (TCM) syndrome differentiation belongs to the pattern of Qi and Blood Deficiency (); (4) Conscious and clear-minded, able to express opinions correctly, and capable of cooperating with treatment; (5) Age between 65 and 80 years old (65 = age = 80); (6) The patient or legally authorized representative has signed the informed consent form. Exclusion criterion: Patients who do not meet any one of the above criteria will not be enrolled.

Exclusion criteria

Exclusion criteria: (1) MNA-SF score > 11 points; (2) End-stage malignant tumor, severe dementia with inability to communicate, acute myocardial ischemia or heart failure attack, New York Heart Association (NYHA) functional class IV, acute upper gastrointestinal bleeding, severe hepatic or renal insufficiency, Parkinson's disease, epilepsy, and other neurological disorders; (3) Whey protein powder supplementation, other oral nutritional supplements, or participation in other nutritional intervention programs within 1 month prior to intervention; (4) Currently participating in other clinical trials, or having participated in other drug clinical trials with less than 3 months since completion. Exclusion criterion: Patients meeting any one of the above criteria will be excluded.

Design outcomes

Primary

MeasureTime frame
Frailty Score;Qi and Blood Deficiency Syndrome Scoring;

Secondary

MeasureTime frame
Body Mass Index;Limb Skeletal Muscle Mass Index;Gait speed;Grip Strength;Mini Nutritional Assessment;25-Hydroxyvitamin D,; Albumin;Prealbumin;Total Protein;electrocardiogram;

Countries

China

Contacts

Public ContactWang Hui

Xi'an City Traditional Chinese Medicine Hospital

11564757@qq.com13572028583

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Apr 4, 2026